Institutional Investor

Updated:

CaraMed Capital

CaraMed Capital is a New Zealand-based healthcare venture capital fund founded in 2020 and headquartered in Auckland. The firm operates as an institutional...

CaraMed Capital

CaraMed Capital is a New Zealand-based healthcare venture capital fund founded in 2020 and headquartered in Auckland. The firm operates as an institutional investor with $50 million in assets under management. CaraMed Capital focuses on investing in healthtech companies located in New Zealand. The firm's portfolio includes one known investment in Xylo Bio, made as part of their Seed VC - II fund on October 27, 2022. As a specialized healthcare VC, CaraMed Capital targets seed-stage opportunities within the health technology sector, supporting the growth of innovative healthtech ventures in the New Zealand market.

General information

Firm type

Institutional Investor

AUM

$50 million

Location

Country

New Zealand

City

Auckland

Corporate office

Auckland, New Zealand

Sector focus

Institutional InvestorNew Zealand

Frequently asked questions

What is CaraMed Capital's investment focus?

CaraMed Capital focuses on investing in healthtech companies based in New Zealand, targeting seed-stage opportunities within the healthcare technology sector.

How much does CaraMed Capital have in assets under management?

CaraMed Capital has $50 million in assets under management.

Where is CaraMed Capital headquartered?

CaraMed Capital is headquartered in Auckland, New Zealand.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Auckland Institutional Investor profiles